In autoimmune and inflammatory drug development, promising therapies frequently demonstrate strong efficacy in preclinical studies — yet fail later in development or in the clinic. While there are many reasons behind these failures, one of the most common challenges is translational relevance: whether the preclinical strategy truly reflects the biology of human disease.
For companies developing therapies within inflammation and autoimmunity, selecting the right models and readouts early can have a major impact on decision-making, resource allocation, and ultimately clinical success.
Inflammatory and autoimmune diseases are biologically complex and highly heterogeneous. Diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease, and lupus involve multiple immune pathways, cell populations, and tissue-specific mechanisms.
Importantly, no single model can fully capture the complexity of human disease.
A treatment that appears highly effective in one experimental setting may fail to demonstrate efficacy when evaluated in a different biological context. This does not necessarily mean that the therapeutic concept is wrong — but it may indicate that the preclinical strategy was too narrow. The key question is whether the selected models, study design, and readouts are biologically relevant to the therapeutic hypothesis and the intended patient population. One common misconception in preclinical development is that selecting a model simply means matching it to a disease indication.
In reality, model selection should be driven by the biological question being asked.
Within rheumatoid arthritis research, for example, different models reflect distinct aspects of disease biology, including adaptive versus innate immune mechanisms, acute versus chronic inflammation, antibody-driven versus T-cell-driven pathology, and tissue destruction versus systemic immune activation. Similarly, within neuroinflammation and multiple sclerosis research, different EAE models can vary substantially in disease kinetics, immune cell involvement, demyelination patterns, relapse-remission profiles, and translational relevance to specific therapeutic mechanisms.
A well-designed preclinical strategy therefore often requires complementary models and readouts rather than relying on a single efficacy study.
While clinical scoring remains important in in vivo models, translational relevance increasingly depends on integrating multiple layers of biological data. Today, robust preclinical studies often combine clinical observations with immune profiling, flow cytometry, cytokine analyses, histopathology, imaging, molecular characterization, and functional readouts to create a more complete understanding of therapeutic impact and mechanism of action. These integrated approaches not only strengthen mechanistic understanding, but also improve confidence in study interpretation and decision-making.
As drug development becomes increasingly targeted and mechanism-driven, mechanistic understanding becomes critical already during preclinical evaluation. A translationally relevant strategy should aim not only to determine whether a therapy works, but also why it works, which pathways are affected, and which cell populations respond.
Combining in vitro, ex vivo, and in vivo approaches can significantly strengthen translational relevance. In vitro and ex vivo systems allow detailed mechanistic investigation under controlled conditions, while in vivo models provide biological context and system-level complexity. When these approaches are integrated thoughtfully, they can improve study interpretation, strengthen mechanistic understanding, identify risks earlier in development, and support biomarker strategies ahead of clinical studies and larger investments.
As inflammatory drug development continues to evolve toward increasingly advanced and targeted therapies, translationally relevant preclinical strategies will become even more important for reducing risk and enabling better decisions throughout development.
Ultimately, translational relevance is not about generating positive data — it is about generating meaningful data that enables informed decisions, reduces development risk, and strengthens confidence ahead of clinical translation. For early preclinical projects this mean, the goal should not simply be to generate data, but to generate meaningful, decision-enabling insight.